Home > Press Releases > Hepatitis B Vaccine Market

Hepatitis B Vaccine Market anticipated reaching up to USD 12.7 Billion by 2035

Report Code: HC-86188  |  Published in: Oct 2025, By MarketGenics  |  Number of pages: 324

Global Hepatitis B Vaccine Market Forecast 2035:

According to the report, the hepatitis B vaccine market is anticipated to grow from USD 6.4 Billion in 2025 to USD 12.7 Billion in 2035 at a CAGR of 7.1% during the forecast. The hepatitis B vaccine market continues to grow, driven by improved immunization coverage programs and the increased utilization of combination vaccines that can simplify childhood vaccination schedules.

Additionally, there is an ongoing collaboration with public health partners in Africa and Southeast Asia, to improve vaccine coverage in rural areas that do not have cold chain supply. Pilot projects are also exploring use of digital applications to enhance tracking and adherence of vaccinations.

Further, ongoing challenges with vaccine hesitancy, logistical capacity, and newly circulating variants of the virus require solution. The market is trending towards thermostable vaccines and single-dose vaccines to improve access and adherence globally across health systems. There is also a continued interest in the development of new adjuvants to improve efficacy and duration of protection in the vaccines. Lastly, public-private partnerships continue to support financing of large coverage voltage programs around the world.

“Key Driver, Restraint, and Growth Opportunity Defining the Global Hepatitis B Vaccine Market

The market for hepatitis B vaccines is supported by global vaccination initiatives and public health programs intended to lessen the prevalence of hepatitis B infection, as well as knowledge of the long duration of the complications of the disease and increasing demand in developing nations. 

Several public health challenges affect the market, including vaccine hesitancy, the high costs associated with vaccination programs and unequal availability of health care in developing nations in which hepatitis B tends to have a higher prevalence. Additional challenges come from the reliance on vaccine cold-chain logistics for vaccines to retain stability, and logistical procurement processes.

Further, increased stable, single-dose, and combination vaccines have created numerous growth opportunities, particularly within the context of enhancing vaccination coverage for the public good through public-private partnerships and adult immunization rates.

"Impact of Global Tariff Policies on the Global Hepatitis B Vaccine Market Growth and Strategy"

The go-to-market for hepatitis B vaccines is influenced by world tariff policies limiting vaccine production and distribution costs. For instance, the cost of vaccine production could be affected when tariffs apply to raw materials or components sourced from other countries (e.g., parts sourced from China) and could create a higher cost of manufacturing into the vaccine distribution cost of manufacturing into the vaccine distribution cost. Increases in manufacturing costs are also prospected to increase the price of vaccines, which will negatively affect vaccination efforts, particularly in places with limited resources by affecting affordability.

However, to relieve cost pressure, manufacturers are evaluating multiple approaches to cut expenses; beginning with optimizing production process, as well as working with government authorities to pursue tariff relief for vaccines or their raw materials. In addition, governments and international organizations may have to negotiate trade policies that would meet objectives that promote public health objectives (e.g. market entry for effective hepatitis B vaccines).

 

Expansion of Global Hepatitis B Vaccine Market

"Rising Global Immunization Efforts, Birth-Dose Campaigns, and Public-Private Partnerships Fuel Global Hepatitis B Vaccine Market Surge"

  • Governments and health organizations are increasing vaccination programs to contain the spread of hepatitis B, particularly in areas with high prevalence of the infection. Newborn vaccination programs which can provide the first dose at birth are being more widespread. The availability of vaccines is also being enhanced through public-private collaboration allowing for increased access and affordability of hepatitis B vaccines which increases demand for vaccines globally.
  • Increased awareness of hepatitis B-related liver disease is contributing to increased adult vaccination in populations at higher risk with vaccine advocacy. Improved combination vaccines are facilitating immunization schedules and increasing coverage rates.

Regional Analysis of Global Hepatitis B Vaccine Market

  • Presently, North America is still the dominant region of the C-arm market, as it possesses advanced level of healthcare infrastructures, and the greatest number of surgical procedures and a strong adoption of mobile imaging technology. More specifically, with steady spending in outpatient surgical centers in the U.S., alongside increased demand for minimally invasive surgeries, it will continue to be the predominant area. Following North America is Europe, with Germany, the U.K., and France gradually adopting AI-based imaging tools into operating rooms.
  • Asia-Pacific is the fastest-growing region, aided by improved access to healthcare, increasing spending on medical equipments and more private hospitals across India, China, and Southeast Asia.
  • Lastly, although growth appears slow in Latin America and Africa to date, demand is growing as government spending increases in basic imaging infrastructure and rural healthcare. Limited C-arm use in these markets is being augmented with local manufacturing and purchasing of refurbished machines, together increasing accessibility to Hepatitis B Vaccine in developing regions.

Key players in the global hepatitis B vaccine market include prominent companies such as Bharat Biotech, Biological E. Limited, Chengdu Institute of Biological Products Co., Ltd., CSL Limited (Seqirus), Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline plc, Hualan Biological, Engineering Inc., Indian Immunologicals Ltd., LG Chem, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec, Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., VBI Vaccines Inc., Walvax Biotechnology Co., Ltd., Zydus Lifesciences Limited, and other key players along with several other key players contributing to market growth through innovation, strategic partnerships, and global expansion.

The Hepatitis B Vaccine Market has been segmented as follows:

Hepatitis B Vaccine Market Analysis, by Type

  • Monovalent Hepatitis B Vaccine
  • Combination Hepatitis B Vaccine

Hepatitis B Vaccine Market Analysis, by Vaccine Technology

  • Recombinant DNA Vaccine
  • Plasma-derived Vaccine
  • Others

Hepatitis B Vaccine Market Analysis, by Dosage Form

  • Single Dose Vial
  • Pre-filled Syringe
  • Multi-dose Vial

Hepatitis B Vaccine Market Analysis, by Age Group

  • Pediatrics
  • Adolescents
  • Adults

Hepatitis B Vaccine Market Analysis, by Route of Administration

  • Intramuscular
  • Subcutaneous

Hepatitis B Vaccine Market Analysis, by End User

  • Hospitals
  • Clinics
  • Vaccination Centers
  • Government Agencies
  • Others

Hepatitis B Vaccine Market Analysis, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Government Supply
  • Online Pharmacies
  • Others

Hepatitis B Vaccine Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact US

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Hepatitis B Vaccine Market Outlook
      • 2.1.1. Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2025-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Hepatitis B Vaccine Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Source Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Global Hepatitis B Vaccine Market Expanding with Preventive Care and Smart Diagnostics
      • 4.1.2. Restraints
        • 4.1.2.1. Global Hepatitis B Vaccine Market Limited by High Storage Needs and Uneven Access
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
      • 4.4.1. Raw Components Sourcing
      • 4.4.2. Manufacturing and Processing
      • 4.4.3. Wholesalers/ E-commerce Platform
      • 4.4.4. End-use/ Customers
    • 4.5. Cost Structure Analysis
      • 4.5.1. Parameter’s Share for Cost Associated
      • 4.5.2. COGP vs COGS
      • 4.5.3. Profit Margin Analysis
    • 4.6. Pricing Analysis
      • 4.6.1. Regional Pricing Analysis
      • 4.6.2. Segmental Pricing Trends
      • 4.6.3. Factors Influencing Pricing
    • 4.7. Porter’s Five Forces Analysis
    • 4.8. PESTEL Analysis
    • 4.9. Global Hepatitis B Vaccine Market Demand
      • 4.9.1. Historical Market Size – (Volume - Million Units and Value - USD Bn), 2021-2024
      • 4.9.2. Current and Future Market Size - Volume - Million Units and Value - USD Bn), 2025–2035
        • 4.9.2.1. Y-o-Y Growth Trends
        • 4.9.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Hepatitis B Vaccine Market Analysis, by Type
    • 6.1. Key Segment Analysis
    • 6.2. Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Type, 2021-2035
      • 6.2.1. Monovalent Hepatitis B Vaccine
      • 6.2.2. Combination Hepatitis B Vaccine
  • 7. Global Hepatitis B Vaccine Market Analysis, by Vaccine Technology
    • 7.1. Key Segment Analysis
    • 7.2. Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Vaccine Technology, 2021-2035
      • 7.2.1. Recombinant DNA Vaccine
      • 7.2.2. Plasma-derived Vaccine
      • 7.2.3. Others
  • 8. Global Hepatitis B Vaccine Market Analysis, by Dosage Form
    • 8.1. Key Segment Analysis
    • 8.2. Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Dosage Form, 2021-2035
      • 8.2.1. Single Dose Vial
      • 8.2.2. Pre-filled Syringe
      • 8.2.3. Multi-dose Vial
  • 9. Global Hepatitis B Vaccine Market Analysis, by Age Group
    • 9.1. Key Segment Analysis
    • 9.2. Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Age Group, 2021-2035
      • 9.2.1. Pediatrics
      • 9.2.2. Adolescents
      • 9.2.3. Adults
  • 10. Global Hepatitis B Vaccine Market Analysis, by Route of Administration
    • 10.1. Key Segment Analysis
    • 10.2. Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
      • 10.2.1. Intramuscular
      • 10.2.2. Subcutaneous
  • 11. Global Hepatitis B Vaccine Market Analysis, by End User
    • 11.1. Key Segment Analysis
    • 11.2. Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by End User, 2021-2035
      • 11.2.1. Hospitals
      • 11.2.2. Clinics
      • 11.2.3. Vaccination Centers
      • 11.2.4. Government Agencies
      • 11.2.5. Others
  • 12. Global Hepatitis B Vaccine Market Analysis, by Distribution Channel
    • 12.1. Key Segment Analysis
    • 12.2. Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Distribution Channel, 2021-2035
      • 12.2.1. Hospital Pharmacies
      • 12.2.2. Retail Pharmacies
      • 12.2.3. Government Supply
      • 12.2.4. Online Pharmacies
      • 12.2.5. Others
  • 13. Global Hepatitis B Vaccine Market Analysis and Forecasts, by Region
    • 13.1. Key Findings
    • 13.2. Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 13.2.1. North America
      • 13.2.2. Europe
      • 13.2.3. Asia Pacific
      • 13.2.4. Middle East
      • 13.2.5. Africa
      • 13.2.6. South America
  • 14. North America Global Hepatitis B Vaccine Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. North America Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Type
      • 14.3.2. Vaccine Technology
      • 14.3.3. Dosage Form
      • 14.3.4. Age Group
      • 14.3.5. Route of Administration
      • 14.3.6. End User
      • 14.3.7. Distribution Channel
      • 14.3.8. Country
        • 14.3.8.1. USA
        • 14.3.8.2. Canada
        • 14.3.8.3. Mexico
    • 14.4. USA Global Hepatitis B Vaccine Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Type
      • 14.4.3. Vaccine Technology
      • 14.4.4. Dosage Form
      • 14.4.5. Age Group
      • 14.4.6. Route of Administration
      • 14.4.7. End User
      • 14.4.8. Distribution Channel
    • 14.5. Canada Global Hepatitis B Vaccine Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Type
      • 14.5.3. Vaccine Technology
      • 14.5.4. Dosage Form
      • 14.5.5. Age Group
      • 14.5.6. Route of Administration
      • 14.5.7. End User
      • 14.5.8. Distribution Channel
    • 14.6. Mexico Global Hepatitis B Vaccine Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Type
      • 14.6.3. Vaccine Technology
      • 14.6.4. Dosage Form
      • 14.6.5. Age Group
      • 14.6.6. Route of Administration
      • 14.6.7. End User
      • 14.6.8. Distribution Channel
  • 15. Europe Global Hepatitis B Vaccine Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. Europe Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Type
      • 15.3.2. Vaccine Technology
      • 15.3.3. Dosage Form
      • 15.3.4. Age Group
      • 15.3.5. Route of Administration
      • 15.3.6. End User
      • 15.3.7. Distribution Channel
      • 15.3.8. Country
        • 15.3.8.1. Germany
        • 15.3.8.2. United Kingdom
        • 15.3.8.3. France
        • 15.3.8.4. Italy
        • 15.3.8.5. Spain
        • 15.3.8.6. Netherlands
        • 15.3.8.7. Nordic Countries
        • 15.3.8.8. Poland
        • 15.3.8.9. Russia & CIS
        • 15.3.8.10. Rest of Europe
    • 15.4. Germany Global Hepatitis B Vaccine Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Type
      • 15.4.3. Vaccine Technology
      • 15.4.4. Dosage Form
      • 15.4.5. Age Group
      • 15.4.6. Route of Administration
      • 15.4.7. End User
      • 15.4.8. Distribution Channel
    • 15.5. United Kingdom Global Hepatitis B Vaccine Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Type
      • 15.5.3. Vaccine Technology
      • 15.5.4. Dosage Form
      • 15.5.5. Age Group
      • 15.5.6. Route of Administration
      • 15.5.7. End User
      • 15.5.8. Distribution Channel
    • 15.6. France Global Hepatitis B Vaccine Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Type
      • 15.6.3. Vaccine Technology
      • 15.6.4. Dosage Form
      • 15.6.5. Age Group
      • 15.6.6. Route of Administration
      • 15.6.7. End User
      • 15.6.8. Distribution Channel
    • 15.7. Italy Global Hepatitis B Vaccine Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Type
      • 15.7.3. Vaccine Technology
      • 15.7.4. Dosage Form
      • 15.7.5. Age Group
      • 15.7.6. Route of Administration
      • 15.7.7. End User
      • 15.7.8. Distribution Channel
    • 15.8. Spain Global Hepatitis B Vaccine Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Type
      • 15.8.3. Vaccine Technology
      • 15.8.4. Dosage Form
      • 15.8.5. Age Group
      • 15.8.6. Route of Administration
      • 15.8.7. End User
      • 15.8.8. Distribution Channel
    • 15.9. Netherlands Global Hepatitis B Vaccine Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Type
      • 15.9.3. Vaccine Technology
      • 15.9.4. Dosage Form
      • 15.9.5. Age Group
      • 15.9.6. Route of Administration
      • 15.9.7. End User
      • 15.9.8. Distribution Channel
    • 15.10. Nordic Countries Global Hepatitis B Vaccine Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Type
      • 15.10.3. Vaccine Technology
      • 15.10.4. Dosage Form
      • 15.10.5. Age Group
      • 15.10.6. Route of Administration
      • 15.10.7. End User
      • 15.10.8. Distribution Channel
    • 15.11. Poland Global Hepatitis B Vaccine Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Type
      • 15.11.3. Vaccine Technology
      • 15.11.4. Dosage Form
      • 15.11.5. Age Group
      • 15.11.6. Route of Administration
      • 15.11.7. End User
      • 15.11.8. Distribution Channel
    • 15.12. Russia & CIS Global Hepatitis B Vaccine Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Type
      • 15.12.3. Vaccine Technology
      • 15.12.4. Dosage Form
      • 15.12.5. Age Group
      • 15.12.6. Route of Administration
      • 15.12.7. End User
      • 15.12.8. Distribution Channel
    • 15.13. Rest of Europe Global Hepatitis B Vaccine Market
      • 15.13.1. Country Segmental Analysis
      • 15.13.2. Type
      • 15.13.3. Vaccine Technology
      • 15.13.4. Dosage Form
      • 15.13.5. Age Group
      • 15.13.6. Route of Administration
      • 15.13.7. End User
      • 15.13.8. Distribution Channel
  • 16. Asia Pacific Global Hepatitis B Vaccine Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. East Asia Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Type
      • 16.3.2. Vaccine Technology
      • 16.3.3. Dosage Form
      • 16.3.4. Age Group
      • 16.3.5. Route of Administration
      • 16.3.6. End User
      • 16.3.7. Distribution Channel
      • 16.3.8. Country
        • 16.3.8.1. China
        • 16.3.8.2. India
        • 16.3.8.3. Japan
        • 16.3.8.4. South Korea
        • 16.3.8.5. Australia and New Zealand
        • 16.3.8.6. Indonesia
        • 16.3.8.7. Malaysia
        • 16.3.8.8. Thailand
        • 16.3.8.9. Vietnam
        • 16.3.8.10. Rest of Asia-Pacific
    • 16.4. China Global Hepatitis B Vaccine Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Type
      • 16.4.3. Vaccine Technology
      • 16.4.4. Dosage Form
      • 16.4.5. Age Group
      • 16.4.6. Route of Administration
      • 16.4.7. End User
      • 16.4.8. Distribution Channel
    • 16.5. India Global Hepatitis B Vaccine Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Type
      • 16.5.3. Vaccine Technology
      • 16.5.4. Dosage Form
      • 16.5.5. Age Group
      • 16.5.6. Route of Administration
      • 16.5.7. End User
      • 16.5.8. Distribution Channel
    • 16.6. Japan Global Hepatitis B Vaccine Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Type
      • 16.6.3. Vaccine Technology
      • 16.6.4. Dosage Form
      • 16.6.5. Age Group
      • 16.6.6. Route of Administration
      • 16.6.7. End User
      • 16.6.8. Distribution Channel
    • 16.7. South Korea Global Hepatitis B Vaccine Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Type
      • 16.7.3. Vaccine Technology
      • 16.7.4. Dosage Form
      • 16.7.5. Age Group
      • 16.7.6. Route of Administration
      • 16.7.7. End User
      • 16.7.8. Distribution Channel
    • 16.8. Australia and New Zealand Global Hepatitis B Vaccine Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Type
      • 16.8.3. Vaccine Technology
      • 16.8.4. Dosage Form
      • 16.8.5. Age Group
      • 16.8.6. Route of Administration
      • 16.8.7. End User
      • 16.8.8. Distribution Channel
    • 16.9. Indonesia Global Hepatitis B Vaccine Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Type
      • 16.9.3. Vaccine Technology
      • 16.9.4. Dosage Form
      • 16.9.5. Age Group
      • 16.9.6. Route of Administration
      • 16.9.7. End User
      • 16.9.8. Distribution Channel
    • 16.10. Malaysia Global Hepatitis B Vaccine Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Type
      • 16.10.3. Vaccine Technology
      • 16.10.4. Dosage Form
      • 16.10.5. Age Group
      • 16.10.6. Route of Administration
      • 16.10.7. End User
      • 16.10.8. Distribution Channel
    • 16.11. Thailand Global Hepatitis B Vaccine Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Type
      • 16.11.3. Vaccine Technology
      • 16.11.4. Dosage Form
      • 16.11.5. Age Group
      • 16.11.6. Route of Administration
      • 16.11.7. End User
      • 16.11.8. Distribution Channel
    • 16.12. Vietnam Global Hepatitis B Vaccine Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Type
      • 16.12.3. Vaccine Technology
      • 16.12.4. Dosage Form
      • 16.12.5. Age Group
      • 16.12.6. Route of Administration
      • 16.12.7. End User
      • 16.12.8. Distribution Channel
    • 16.13. Rest of Asia Pacific Global Hepatitis B Vaccine Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Type
      • 16.13.3. Vaccine Technology
      • 16.13.4. Dosage Form
      • 16.13.5. Age Group
      • 16.13.6. Route of Administration
      • 16.13.7. End User
      • 16.13.8. Distribution Channel
  • 17. Middle East Global Hepatitis B Vaccine Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Middle East Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Type
      • 17.3.2. Vaccine Technology
      • 17.3.3. Dosage Form
      • 17.3.4. Age Group
      • 17.3.5. Route of Administration
      • 17.3.6. End User
      • 17.3.7. Distribution Channel
      • 17.3.8. Country
        • 17.3.8.1. Turkey
        • 17.3.8.2. UAE
        • 17.3.8.3. Saudi Arabia
        • 17.3.8.4. Israel
        • 17.3.8.5. Rest of Middle East
    • 17.4. Turkey Global Hepatitis B Vaccine Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Type
      • 17.4.3. Vaccine Technology
      • 17.4.4. Dosage Form
      • 17.4.5. Age Group
      • 17.4.6. Route of Administration
      • 17.4.7. End User
      • 17.4.8. Distribution Channel
    • 17.5. UAE Global Hepatitis B Vaccine Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Type
      • 17.5.3. Vaccine Technology
      • 17.5.4. Dosage Form
      • 17.5.5. Age Group
      • 17.5.6. Route of Administration
      • 17.5.7. End User
      • 17.5.8. Distribution Channel
    • 17.6. Saudi Arabia Global Hepatitis B Vaccine Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Type
      • 17.6.3. Vaccine Technology
      • 17.6.4. Dosage Form
      • 17.6.5. Age Group
      • 17.6.6. Route of Administration
      • 17.6.7. End User
      • 17.6.8. Distribution Channel
    • 17.7. Israel Global Hepatitis B Vaccine Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Type
      • 17.7.3. Vaccine Technology
      • 17.7.4. Dosage Form
      • 17.7.5. Age Group
      • 17.7.6. Route of Administration
      • 17.7.7. End User
      • 17.7.8. Distribution Channel
    • 17.8. Rest of Middle East Global Hepatitis B Vaccine Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Type
      • 17.8.3. Vaccine Technology
      • 17.8.4. Dosage Form
      • 17.8.5. Age Group
      • 17.8.6. Route of Administration
      • 17.8.7. End User
      • 17.8.8. Distribution Channel
  • 18. Africa Global Hepatitis B Vaccine Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Africa Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Type
      • 18.3.2. Vaccine Technology
      • 18.3.3. Dosage Form
      • 18.3.4. Age Group
      • 18.3.5. Route of Administration
      • 18.3.6. End User
      • 18.3.7. Distribution Channel
      • 18.3.8. Country
        • 18.3.8.1. South Africa
        • 18.3.8.2. Egypt
        • 18.3.8.3. Nigeria
        • 18.3.8.4. Algeria
        • 18.3.8.5. Rest of Africa
    • 18.4. South Africa Global Hepatitis B Vaccine Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Type
      • 18.4.3. Vaccine Technology
      • 18.4.4. Dosage Form
      • 18.4.5. Age Group
      • 18.4.6. Route of Administration
      • 18.4.7. End User
      • 18.4.8. Distribution Channel
    • 18.5. Egypt Global Hepatitis B Vaccine Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Type
      • 18.5.3. Vaccine Technology
      • 18.5.4. Dosage Form
      • 18.5.5. Age Group
      • 18.5.6. Route of Administration
      • 18.5.7. End User
      • 18.5.8. Distribution Channel
    • 18.6. Nigeria Global Hepatitis B Vaccine Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Type
      • 18.6.3. Vaccine Technology
      • 18.6.4. Dosage Form
      • 18.6.5. Age Group
      • 18.6.6. Route of Administration
      • 18.6.7. End User
      • 18.6.8. Distribution Channel
    • 18.7. Algeria Global Hepatitis B Vaccine Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Type
      • 18.7.3. Vaccine Technology
      • 18.7.4. Dosage Form
      • 18.7.5. Age Group
      • 18.7.6. Route of Administration
      • 18.7.7. End User
      • 18.7.8. Distribution Channel
    • 18.8. Rest of Africa Global Hepatitis B Vaccine Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Type
      • 18.8.3. Vaccine Technology
      • 18.8.4. Dosage Form
      • 18.8.5. Age Group
      • 18.8.6. Route of Administration
      • 18.8.7. End User
      • 18.8.8. Distribution Channel
  • 19. South America Global Hepatitis B Vaccine Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Central and South Africa Global Hepatitis B Vaccine Market Size (Volume - Million Units and Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Type
      • 19.3.2. Vaccine Technology
      • 19.3.3. Dosage Form
      • 19.3.4. Age Group
      • 19.3.5. Route of Administration
      • 19.3.6. End User
      • 19.3.7. Distribution Channel
      • 19.3.8. Country
        • 19.3.8.1. Brazil
        • 19.3.8.2. Argentina
        • 19.3.8.3. Rest of South America
    • 19.4. Brazil Global Hepatitis B Vaccine Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Type
      • 19.4.3. Vaccine Technology
      • 19.4.4. Dosage Form
      • 19.4.5. Age Group
      • 19.4.6. Route of Administration
      • 19.4.7. End User
      • 19.4.8. Distribution Channel
    • 19.5. Argentina Global Hepatitis B Vaccine Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Type
      • 19.5.3. Vaccine Technology
      • 19.5.4. Dosage Form
      • 19.5.5. Age Group
      • 19.5.6. Route of Administration
      • 19.5.7. End User
      • 19.5.8. Distribution Channel
    • 19.6. Rest of South America Global Hepatitis B Vaccine Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Type
      • 19.6.3. Vaccine Technology
      • 19.6.4. Dosage Form
      • 19.6.5. Age Group
      • 19.6.6. Route of Administration
      • 19.6.7. End User
      • 19.6.8. Distribution Channel
  • 20. Key Players/ Company Profile
    • 20.1. Bharat Biotech
      • 20.1.1. Company Details/ Overview
      • 20.1.2. Company Financials
      • 20.1.3. Key Customers and Competitors
      • 20.1.4. Business/ Industry Portfolio
      • 20.1.5. Product Portfolio/ Specification Details
      • 20.1.6. Pricing Data
      • 20.1.7. Strategic Overview
      • 20.1.8. Recent Developments
    • 20.2. Biological E. Limited
    • 20.3. Chengdu Institute of Biological Products Co., Ltd.
    • 20.4. CSL Limited (Seqirus)
    • 20.5. Dynavax Technologies Corporation
    • 20.6. Emergent BioSolutions Inc.
    • 20.7. GlaxoSmithKline plc
    • 20.8. Hualan Biological Engineering Inc.
    • 20.9. Indian Immunologicals Ltd.
    • 20.10. LG Chem
    • 20.11. Merck & Co., Inc.
    • 20.12. Mitsubishi Tanabe Pharma Corporation
    • 20.13. Panacea Biotec
    • 20.14. Pfizer Inc.
    • 20.15. Sanofi
    • 20.16. Serum Institute of India Pvt. Ltd.
    • 20.17. Shenzhen Kangtai Biological Products Co., Ltd.
    • 20.18. VBI Vaccines Inc.
    • 20.19. Walvax Biotechnology Co., Ltd.
    • 20.20. Zydus Lifesciences Limited
    • 20.21. Other key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation